An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain DAT and SERT Occupancy, Pharmacokinetics and Safety of Single Oral Doses of GSK1360707, Using 11C- PE2I and 11C-DASB as PET Ligands.

Trial Profile

An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain DAT and SERT Occupancy, Pharmacokinetics and Safety of Single Oral Doses of GSK1360707, Using 11C- PE2I and 11C-DASB as PET Ligands.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs GSK 1360707 (Primary)
  • Indications Anxiety disorders; Depressive disorders
  • Focus Pharmacokinetics
  • Most Recent Events

    • 25 Jun 2011 Trial phase changed from II to I as reported by ClinicalTrials.gov.
    • 09 Jul 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top